logo
logo
HLN stock ticker logo

Haleon plc

NYSE•HLN
執行長: Mr. Brian James McNamara
板塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
上市日期: 2022-07-25
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
聯絡資訊
The Heights, Building 5, First Floor, Weybridge, KT13 0NY, United Kingdom
44-1932-822000
www.haleon.com
市值
$46.01B
本益比 (TTM)
22.7
57.6
股息率
1.5%
52周最高
$11.42
52周最低
$8.71
52周範圍
60%
排名34Top 27.8%
4.7
F-Score
改良版 Piotroski 分析
基於 6 年期基本面
一般 • 4.7 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2020-2025

財務儀表板

Q4 2025 數據

營業收入

$7.39B+0.00%
近4季度走勢

每股收益

$0.25+0.00%
近4季度走勢

自由現金流

$1.68B+0.00%
近4季度走勢

2024 Annual 財報亮點

核心亮點

Organic Revenue Growth Strong Organic revenue grew 5.0% for 2024; reported revenue declined (0.6)% to £11.2bn due to FX headwinds.
Profitability and Margin Expansion Operating profit reached £2.2bn, up 10.5% reported; adjusted operating margin grew 100bps organically to 22.3%.
Deleveraging and Shareholder Returns Returned over £1bn to shareholders via buybacks and dividends; Net debt/adjusted EBITDA reduced to 2.8x.
Health Inclusivity Target Achieved Empowered over 50m people against health inclusivity goal, achieving the 2025 target one year ahead of plan.

關注風險

FX Headwinds Impact Reported Revenue Adverse foreign exchange movements caused £421m negative impact on reported revenue decline of (0.6)%.
Increased Cyber Security Threat Profile Cyber security risk increased due to rising sophistication of threats, third-party exposure, and new risks from AI adoption.
Geopolitical Instability Risk Rises Geopolitical instability risk increased reflecting ongoing conflicts and rising protectionism impacting global operations and talent movement.
Supply Chain Resilience Tested Global sourcing network faces disruption from geopolitical instability, extreme weather, and commodity volatility impacting service levels.

未來展望

Medium-Term Revenue Guidance Medium-term guidance targets annual organic revenue growth between 4-6% supported by portfolio strength.
2025 Profit Growth Ahead Expecting 2025 organic revenue growth of 4-6%, with organic operating profit growth anticipated to be ahead of revenue.
Continued Capital Allocation Discipline Board approved £500m capital allocation for share buybacks in 2025, balancing investment and shareholder returns.
Evolving Strategy and Culture Priorities for 2025 include continued transformation into agile business and evolving culture to capitalize on opportunities.

同行對比

營業收入 (TTM)

CAH stock ticker logoCAH
$244.49B
+10.1%
HUM stock ticker logoHUM
$129.66B
+10.1%
TAK stock ticker logoTAK
$30.01B
-2.0%

毛利率 (最新季度)

INSM stock ticker logoINSM
82.5%
-18.6pp
EW stock ticker logoEW
78.3%
-2.7pp
ZTS stock ticker logoZTS
68.9%
+2.4pp

關鍵指標

股票代碼
市值
本益比 (TTM)
股東權益報酬率 (TTM)
負債率
BDX$61.57B27.66.9%35.6%
TAK$56.11B78.81.6%31.5%
ZTS$53.87B20.058.2%61.4%

長期趨勢

近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
1.3%
溫和增長
4季度淨利複合增長率
7.7%
盈利能力逐步提升
現金流穩定性
75%
現金流波動較大

深度研究

下次財報:2026年4月29日
|
每股收益:-
|
營業收入:-
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表
過去12個月
無資料